Prospective cross-sectional study on faecal immunochemical tests: Sex specific cut-off values to obtain equal sensitivity for colorectal cancer?

BMC Gastroenterology

Volumn 14, Issue 1, 2014, Pages

  van Turenhout, Sietze T ^a   Oort, Frank A ^a   van der Hulst, René WM ^b   Visscher, Arjen P ^a,b   Terhaar sive Droste, Jochim S ^a   Scholten, Pieter ^c   Bouman, Anneke A ^a   Meijer, Gerrit A ^a   Mulder, Chris J J ^a   van Rossum, Leo G M ^a,d   Coupé, Veerle M H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Orthopaedic Surgery   (Netherlands)

^c ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Advanced adenoma; Colorectal cancer screening; Fecal immunochemical test; Sex

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER LOCALIZATION; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FECAL IMMUNOCHEMICAL TEST; FECES ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; COLORECTAL NEOPLASMS; EARLY DIAGNOSIS; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; PROCEDURES; VERY ELDERLY; YOUNG ADULT;

HEMOGLOBIN;

ADULT; AGED; AGED, 80 AND OVER; COLONOSCOPY; COLORECTAL NEOPLASMS; CROSS-SECTIONAL STUDIES; EARLY DETECTION OF CANCER; FEMALE; HEMOGLOBINS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; PROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84964315563     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/s12876-014-0217-7     Document Type: Article

References (22)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, et al: Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007, 99:1462-1470.
3. Brenner H, Haug U, Hundt S: Sex differences in performance of fecal occult blood testing. Am J Gastroenterol 2010, 105:2457-2464.
4. Oort FA, Terhaar Sive Droste JS, Van Der Hulst RW, Van Heukelem HA, Loffeld RJ, Wesdorp IC et al.: Colonoscopy controlled intraindividual comparisons to screen relevant neoplasia-fecal immunochemical test versus guaiac based fecal occult blood test. Aliment Pharmacol Ther 2010, 31(3):432-439.
5. Oort FA, van Turenhout ST, Coupe VM, van der Hulst RW, Wesdorp EI, Terhaar Sive Droste JS, et al: Double sampling of a faecal immunochemical test is not superior to single sampling for detection of colorectal neoplasia: a colonoscopy controlled prospective cohort study. BMC Cancer 2011, 11:434.
6. Terhaar Sive Droste JS, Oort FA, Van Der Hulst RW, Van Heukelem HA, Loffeld RJ, van Turenhout ST et al.: Higher Fecal Immunochemical Test cut-off levels: lower positivity rates but still acceptable detection rates for early stage colorectal cancers. Cancer Epidemiol Biomarkers Prev 2011, 20(2):272-280.
7. Rozen P, Waked A, Vilkin A, Levi Z, Niv Y: Evaluation of a desk top instrument for the automated development and immunochemical quantification of fecal occult blood. Med Sci Monit 2006, 12:MT27-MT32.
8. Ciatto S, Martinelli F, Castiglione G, Mantellini P, Rubeca T, Grazzini G, et al: Association of FOBT-assessed faecal Hb content with colonic lesions detected in the Florence screening programme. Br J Cancer 2007, 96:218-221.
9. Haug U, Kuntz KM, Knudsen AB, Hundt S, Brenner H: Sensitivity of immunochemical faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia. Br J Cancer 2011, 104:1779-1785.
10. Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, et al: The National Polyp Study. Eur J Cancer Prev 1993, 2(Suppl 2):83-87.
11. Rex DK, Kahi CJ, Levin B, Smith RA, Bond JH, Brooks D, et al: Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer. CA Cancer J Clin 2006, 56:160-167.
12. Ferlitsch M, Reinhart K, Pramhas S, Wiener C, Gal O, Bannert C, et al: Sex-specific prevalence of adenomas, advanced adenomas, and colorectal cancer in individuals undergoing screening colonoscopy. JAMA 2011, 306:1352-1358.
13. Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H: Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum 2010, 53:57-64.
14. Khalid-de Bakker CA, Jonkers DM, Sanduleanu S, de Bruine AP, Meijer GA, Janssen JB, et al: Test performance of immunologic fecal occult blood testing and sigmoidoscopy compared with primary colonoscopy screening for colorectal advanced adenomas. Cancer Prev Res (Phila) 2011, 4:1563-1571.
15. Rao SS, Kuo B, McCallum RW, Chey WD, DiBaise JK, Hasler WL, et al: Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation. Clin Gastroenterol Hepatol 2009, 7:537-544.
16. Rozen P, Levi Z, Hazazi R, Waked A, Vilkin A, Maoz E, et al: Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed. Aliment Pharmacol Ther 2009, 29:906-917.
17. Wu D, Erwin D, Rosner GL: Estimating key parameters in FOBT screening for colorectal cancer. Cancer Causes Control 2009, 20:41-46.
18. Steele RJ, Kostourou I, McClements P, Watling C, Libby G, Weller D, et al: Effect of gender, age and deprivation on key performance indicators in a FOBTbased colorectal screening programme. J Med Screen 2010, 17:68-74.
19. von Wagner C, Baio G, Raine R, Snowball J, Morris S, Atkin W, Obichere A, Handley G, Logan RF, Rainbow S, Smith S, Halloran S, Wardle J: Inequalities in participation in an organized national colorectal cancer screening programme: results from the first 2.6 million invitations in England. Int J Epidemiol 2011, 40(3):712-8.
20. Lansdorp-Vogelaar I, Van Ballegooijen M, Zauber AG, Boer R, Wilschut J, Winawer SJ, et al: Individualizing colonoscopy screening by sex and race. Gastrointest Endosc 2009, 70:96-108.
21. Imperiale TF: Quantitative immunochemical fecal occult blood tests: is it time to go back to the future? Ann Intern Med 2007, 146:309-311.
22. van Turenhout ST, van Rossum LG, Oort FA, Laheij RJ, van Rijn AF, Terhaar Sive Droste JS, et al: Similar fecal immunochemical test results in screening and referral colorectal cancer. World J Gastroenterol 2012, 18:5397-5403.